Key Updates
Berkshire Hathaway shares fell 2.05% to $732,555 since the last report, giving back part of September’s rally. The headline event was the announcement of the acquisition of OxyChem from Occidental Petroleum for $9.7 billion, underscoring Buffett’s continued active investment strategy. Despite the short-term pullback, the company still posts a solid year-to-date gain of +7.58%.
Current Trend
The stock is consolidating after September’s bounce. Over the past six months the share has slipped 6.56%, yet it remains up +7.58% since the start of the year. Short-term metrics show seller pressure: down 0.22% on the day, 2.42% over the week and 1.05% for the month. The current level of $732,555 is near September’s opening range, potentially forming a support zone.
Investment Thesis
Berkshire Hathaway continues to diversify through large chemical-sector acquisitions, adding high-margin assets to its portfolio. The conglomerate demonstrates the ability to generate stable cash flow and allocate capital efficiently amid market volatility. Its placement among the top-10 best-performing stocks over the past five years validates the strength of its business model.
Thesis Status
The investment case remains intact and is reinforced by the OxyChem deal. The $9.7 billion purchase shows management’s willingness to make big bets during periods of market uncertainty. The short-term correction does not alter the company’s fundamental advantages; instead, it creates buying opportunities for long-term investors.
Key Drivers
The primary catalyst was the announcement of the $9.7 billion OxyChem acquisition, which strengthens Berkshire’s position in chemicals. The deal helps Occidental reduce its debt load, highlighting the mutually beneficial nature of the transaction. Analysts note the steady stock performance amid fundamental valuation metrics.
Technical Picture
The price is trading in a $730,000-$750,000 range after September’s rebound from lows. The current level of $732,555 sits near the lower edge of the trading corridor, which could attract buyers. A six-month pullback of 6.56% suggests the distribution phase may be ending, while the 7.58% year-to-date gain keeps the long-term outlook bullish.
Bull Case
- Strategic $9.7 billion OxyChem acquisition expands exposure to a high-margin chemical sector (source)
- Placement in the top-10 best-performing stocks over the last five years confirms the strength of the business model (source)
- Positive year-to-date performance of +7.58% shows resilience to market volatility (source)
- Active investment strategy by management capitalizes on market opportunities (source)
- Formation of a support zone at current levels after the six-month correction (source)
Bear Case
- The six-month pullback of 6.56% indicates ongoing seller pressure (source)
- Short-term downside: down 2.42% over the week and 1.05% for the month (source)
- The high price of the OxyChem acquisition could weigh on return on capital (source)
- Uncertainty in the insurance sector, where specialty players trade at a premium (source)
- Consolidation in a narrow range may lead to a support break if market conditions worsen (source)